1. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. (February 2022) Authors: Peyrin-Biroulet, Laurent; Hart, Ailsa; Bossuyt, Peter; Long, Millie; Allez, Matthieu; Juillerat, Pascal; Armuzzi, Alessandro; Loftus, Edward V; Ostad-Saffari, Elham; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Lacey, Stuart; Sandborn, William J; Aguilar, Humberto; Ah... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. (February 2022) Authors: Danese, Silvio; Colombel, Jean-Frederic; Lukas, Milan; Gisbert, Javier P; D'Haens, Geert; Hayee, Bu'hussain; Panaccione, Remo; Kim, Hyun-Soo; Reinisch, Walter; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Tang, Meina Tao; Schreiber, Stefan; Aboo, Nazimuddin; ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. Issue 11 (November 2017) Authors: Gonczi, Lorant; Gecse, Krisztina B.; Vegh, Zsuzsanna; Kurti, Zsuzsanna; Rutka, Mariann; Farkas, Klaudia; Golovics, Petra A.; Lovasz, Barbara D.; Banai, Janos; Bene, Laszlo; Gasztonyi, Bea; Kristof, Tunde; Lakatos, Laszlo; Miheller, Pal; Nagy, Ferenc; Palatka, Karoly; Papp, Maria; Patai, Arpad; Sa... Journal: Inflammatory bowel diseases Issue: Volume 23:Issue 11(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗